{"id":"nvk-002-concentration-2","safety":{"commonSideEffects":[{"rate":null,"effect":"null"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of NVK-002 Concentration 2 is not well understood, but it is believed to work by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"NVK-002 Concentration 2 is a small molecule that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:41.077Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 for phase_3"}]},"trialDetails":[{"nctId":"NCT03350620","phase":"PHASE3","title":"CHAMP: Study of NVK-002 in Children With Myopia","status":"COMPLETED","sponsor":"Vyluma, Inc.","startDate":"2017-11-20","conditions":"Myopia","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NVK-002 Conc 2"],"phase":"phase_3","status":"active","brandName":"NVK-002 Concentration 2","genericName":"NVK-002 Concentration 2","companyName":"Vyluma, Inc.","companyId":"vyluma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NVK-002 Concentration 2 is a small molecule that targets the molecular target. Used for Phase 3 for phase_3.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}